Connect with us
Grifols secured a $21 million grant from the Michael J. Fox Foundation to study plasma biomarkers for early Parkinson’s detection. The 10-year Chronos PD project will...
In 2024, Spanish pharma focused on stabilizing finances rather than expanding, with six major players seeing an 18% profit drop compared to 2023. While Faes Farma...
Grifols faced a turbulent 2024 with leadership changes, legal battles, and debt refinancing. Accusations by Gotham City Research and a rejected takeover bid from Brookfield added...
Mason Capital, owning 2.1% of Grifols' Class A shares, seeks Tomás Dagá's resignation, citing governance concerns and shareholder value loss. The fund demands transparency on Dagá’s...
Spanish pharmaceutical stocks dropped 10% in November, led by Rovi's 17.5% plunge amid profit and turnover declines. Grifols also fell 16%, impacted by OPA cancellation and...
Gotham City raises doubts about Grifols following Brookfield's withdrawal from a takeover bid, claiming the firm lacked access to crucial data. Grifols shares dropped 14%, compounding...
Brookfield agreed with Santander and Deutsche Bank to raise €11 billion for Grifols' debt refinancing, potentially Spain's largest syndicated loan. This funding is vital for Brookfield’s...
Grifols achieved its best score in the S&P Global Sustainability ranking with 70 points, improving by seven from last year. The ranking recognized its advancements in...
GigaGen will develop a recombinant polyclonal antibody therapy for botulinum neurotoxins and another biological threat. Grifols expects €930 million in U.S. revenues from Yimmugo, an immunoglobulin...
Rovi shares fell 10.5%, contributing to a 1.9% decline in Spain's pharmaceutical sector. Almirall also dropped 1.2%, while PharmaMar and Grifols rose 22.4% and 1.4%, respectively....